GlycoMimetics to Participate at Upcoming Roth Investor Conference

Rhea-AI Summary

GlycoMimetics, Inc. (Nasdaq: GLYC) will participate in the 34th Annual Roth Conference on March 14-15 in Laguna Niguel, California. CEO Harout Semerjian and CFO Brian Hahn will attend, with a fireside chat hosted by Research Analyst Zegbeh Jallah. An archived recording will be available on the GlycoMimetics website starting March 15 at approximately 2:00 p.m. PST. The company focuses on developing glycobiology-based therapies for cancers and inflammatory diseases. For more information, visit www.glycomimetics.com.

ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that the Company will participate at the 34^th Annual Roth Conference in Laguna Niguel, California, March 14 and 15.

Chief Executive Officer Harout Semerjian and Chief Financial Officer Brian Hahn will attend in person. Research Analyst Zegbeh Jallah, Ph.D. will host a fireside chat with Mr. Semerjian. An archived recording of the chat will be available for thirty days on the GlycoMimetics website at https://ir.glycomimetics.com/investor-relations, beginning Tuesday, March 15 at approximately 2:00 p.m. PST.

About GlycoMimetics, Inc.

GlycoMimetics is a clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including acute myeloid leukemia (AML), and for inflammatory diseases with high unmet need. The Company’s science is based on an understanding of the role that carbohydrates play on the surface of every living cell and applying its specialized chemistry platform to discover small molecule drugs, known as glycomimetics, which alter these carbohydrate-mediated pathways in a variety of disease states, including signaling in cancer and inflammation. As a leader in this space, GlycoMimetics is leveraging this unique targeted approach to advance its pipeline of wholly owned drug candidates, with the goal of developing transformative therapies for serious diseases. GlycoMimetics is located in Rockville, Maryland in the BioHealth Capital Region. Learn more at www.glycomimetics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220308006322/en/

Investor and Media Contact:

Shari Annes

Phone: 650-888-0902

Email: sannes@annesassociates.com

Source: GlycoMimetics, Inc.

FAQ

When is GlycoMimetics participating in the Roth Conference?

GlycoMimetics will participate in the Roth Conference on March 14-15, 2023.

Who will represent GlycoMimetics at the Roth Conference?

CEO Harout Semerjian and CFO Brian Hahn will represent GlycoMimetics.

What can we expect from the fireside chat at the Roth Conference?

The fireside chat will feature CEO Harout Semerjian and will be hosted by Research Analyst Zegbeh Jallah.

Is the fireside chat available for later viewing?

Yes, an archived recording will be available on the GlycoMimetics website starting March 15, 2023.

What is the focus of GlycoMimetics as a company?

GlycoMimetics focuses on discovering and developing glycobiology-based therapies for cancers and inflammatory diseases.